Loading...
  • present antigen
  • A number of studies have shown that malignant B cells can process and present antigen to T cells in vitro , including the presentation of epitopes derived from their own unique immunoglobulin idiotype to CD4 + and CD8 + T cells ( 5 - 7 ). (aacrjournals.org)
  • induces
  • Here, this paradigm will be advanced employing the tumor marker GCC, which induces immune responses that oppose metastatic colorectal cancer in preclinical models, without autoimmunity. (clinicaltrials.gov)
  • contributes
  • Indoleamine 2,3-dioxygenase (IDO) is an immunosuppressive enzyme that contributes to tolerance in a number of biological settings. (aacrjournals.org)
  • The regulatory molecule CTLA-4, expressed by host T cells, contributes to tumor tolerance but can be blocked by the anti-CTLA-4 monoclonal antibody ipilimumab. (aacrjournals.org)
  • vitro
  • In attempting to address these issues, we previously showed that a murine B-cell lymphoma (A20) transfected to express the model antigen influenza hemagglutinin (HA) activates HA-specific CD4 + T cells from T-cell receptor (TCR) transgenic mice in vitro . (aacrjournals.org)
  • mechanism
  • The immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) has been implicated as an immunosuppressive and tolerogenic mechanism contributing to maternal tolerance toward the allogeneic fetus ( 1 ), regulation of autoimmune disorders ( 2 - 5 ), and suppression of transplant rejection ( 6 , 7 ). (aacrjournals.org)
  • Regional intra or perilymphatic and/or intratumoral or peritumoral low dose cytokine therapy may have important therapeutic effects in SCCHN patients and constitute an additional anti-tumor mechanism of action different and distinct from current SOC. (clinicaltrials.gov)
  • transgenic
  • To approach these questions, we have developed a transgenic mouse which expresses the tumor-specific antigen P91A. (wiley.com)
  • In transgenic tissue, the H-2L d /P91A complex is expressed in isolation from other tumor-associated antigens, allowing definition of the immune response to a single defined tumor antigen, a situation closely analogous to events during tumorigenesis. (wiley.com)
  • reduces
  • An inhibitor of the pleckstrin homology domain of AKT, perifosine, effectively blocks PI3K signaling and significantly reduces tumor formation in mutant and wildtype PTEN orthotopic breast carcinoma xenograft mouse models. (army.mil)
  • mice
  • and ( d ) tumor-bearing mice vaccinated with yeast-CEA show a reduction in tumor burden and increased overall survival compared to mock-treated or control yeast-vaccinated mice in both pulmonary metastasis and s.c. pancreatic tumor models. (aacrjournals.org)
  • Additionally, tumor therapy studies have shown that when tumor-bearing mice are vaccinated with S. cerevisiae constructs expressing the appropriate point-mutated Ras protein, tumor growth is slowed ( 11 , 14 ). (aacrjournals.org)
  • A similar phenotype was observed in MCP-1- and CCR2-deficient mice, suggesting that this cytokine axis regulates presence of antigen-presenting inflammatory monocytes in the spleen. (sciencemag.org)
  • immune response
  • Opposing inhibitory signals, such as those delivered by cytotoxic T-lymphocyte antigen 4 (CTLA-4), modulate the immune response and increase the threshold for T-cell activation ( 4 - 6 ). (aacrjournals.org)
  • Despite the existence of this tumor-antigen and the well-documented expression of MHC class I and class II molecules ( 3 ), as well as costimulatory molecules by a majority of human B-cell malignancies, no spontaneous clinically significant immune response in these diseases has been documented ( 4 ). (aacrjournals.org)
  • carcinomas
  • GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. (thermofisher.com)
  • Overexpression of Twist has been shown to be associated with poor prognosis and drug resistance for many carcinomas and other tumor types. (aacrjournals.org)
  • immunosurveillance
  • The activation of all these suppressive pathways seems to be regulated by IL4Rα, because genetic ablation or pharmacologic down-regulation of this receptor on MDSCs restores tumor-specific T-cell responsiveness and immunosurveillance ( 17 , 22 ). (aacrjournals.org)
  • recurrence
  • However, there are a number of limitations with their use, including tumour recurrence, the requirement for multiple doses and high -cost production. (bl.uk)